These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
285 related articles for article (PubMed ID: 37818357)
1. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma. Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S Front Immunol; 2023; 14():1128244. PubMed ID: 37818357 [TBL] [Abstract][Full Text] [Related]
2. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma. Zhang W; Li L; Bian PP; Luo QP; Xiong ZT Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of Pleckstrin Homology Domain-Containing Family A Member 4 Is Correlated with Poor Prognostic Outcomes and Immune Infiltration in Lower-Grade Glioma. Huang B; Pan W; Wang W; Wang Y; Liu P; Geng W Dis Markers; 2022; 2022():1292648. PubMed ID: 36408463 [TBL] [Abstract][Full Text] [Related]
4. Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118 [TBL] [Abstract][Full Text] [Related]
5. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma. Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355 [TBL] [Abstract][Full Text] [Related]
6. FAM109B plays a tumorigenic role in low-grade gliomas and is associated with tumor-associated macrophages (TAMs). Zhang Z; Xiao Y; Zhao S; Liu J; Zeng J; Xiao F; Liao B; Shan X; Zhu H; Guo H J Transl Med; 2024 Sep; 22(1):833. PubMed ID: 39256832 [TBL] [Abstract][Full Text] [Related]
7. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666 [TBL] [Abstract][Full Text] [Related]
8. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma. Hao YP; Wang WY; Qiao Q; Li G Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884 [TBL] [Abstract][Full Text] [Related]
9. The combined signatures of telomere and immune cell landscape provide a prognostic and therapeutic biomarker in glioma. Han X; Yan Z; Fan K; Guan X; Hu B; Li X; Ou Y; Cui B; An L; Zhang Y; Gong J Front Immunol; 2023; 14():1220100. PubMed ID: 37662954 [TBL] [Abstract][Full Text] [Related]
10. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment. Wang F; Tao Z; Tian Z; Jin J; Dong J; Dai Y; Yu W; Tang B; Hu S Front Genet; 2022; 13():874896. PubMed ID: 35865011 [No Abstract] [Full Text] [Related]
11. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. Li Y; Feng Y; Luo F; Peng G; Li Y Front Immunol; 2022; 13():1089792. PubMed ID: 36726969 [TBL] [Abstract][Full Text] [Related]
12. PLEKHA4 promotes glioblastoma progression through apoptosis inhibition, tumor cell migration, and macrophage infiltration. He Y; Zheng W; Huo Y; Sa L; Zhang H; He G; Shang P Immunobiology; 2023 Nov; 228(6):152746. PubMed ID: 37980830 [TBL] [Abstract][Full Text] [Related]
13. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma. Ma W; Mei P World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196 [TBL] [Abstract][Full Text] [Related]
14. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry. Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of the prognostic and role in immune cell infiltration of MSR1 expression in lower-grade gliomas. Ji Q; Huang K; Jiang Y; Lei K; Tu Z; Luo H; Zhu X Cancer Med; 2022 May; 11(9):2020-2035. PubMed ID: 35142109 [TBL] [Abstract][Full Text] [Related]
16. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma. Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J Front Oncol; 2021; 11():654350. PubMed ID: 33954112 [TBL] [Abstract][Full Text] [Related]
17. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas. Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP Front Immunol; 2022; 13():933973. PubMed ID: 36045691 [TBL] [Abstract][Full Text] [Related]
18. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy. Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X Front Immunol; 2022; 13():899710. PubMed ID: 35677036 [TBL] [Abstract][Full Text] [Related]
19. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas. Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438 [TBL] [Abstract][Full Text] [Related]
20. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas. Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]